S&P 500   4,585.36 (+0.40%)
DOW   34,529.70 (+0.13%)
QQQ   395.37 (+0.39%)
AAPL   168.35 (+1.85%)
MSFT   335.93 (+1.62%)
FB   317.19 (-2.24%)
GOOGL   2,879.63 (+1.47%)
AMZN   3,496.29 (-0.31%)
TSLA   1,137.60 (-0.63%)
NVDA   323.38 (-1.03%)
BABA   125.05 (-1.94%)
NIO   39.58 (+1.15%)
CGC   10.31 (-3.73%)
AMD   153.32 (-3.19%)
GE   95.00 (+0.01%)
MU   87.25 (+3.87%)
T   22.45 (-1.66%)
F   19.98 (+4.12%)
DIS   144.60 (-0.21%)
PFE   54.41 (+1.27%)
ACB   6.22 (-3.12%)
AMC   31.31 (-7.75%)
BA   193.13 (-2.39%)
S&P 500   4,585.36 (+0.40%)
DOW   34,529.70 (+0.13%)
QQQ   395.37 (+0.39%)
AAPL   168.35 (+1.85%)
MSFT   335.93 (+1.62%)
FB   317.19 (-2.24%)
GOOGL   2,879.63 (+1.47%)
AMZN   3,496.29 (-0.31%)
TSLA   1,137.60 (-0.63%)
NVDA   323.38 (-1.03%)
BABA   125.05 (-1.94%)
NIO   39.58 (+1.15%)
CGC   10.31 (-3.73%)
AMD   153.32 (-3.19%)
GE   95.00 (+0.01%)
MU   87.25 (+3.87%)
T   22.45 (-1.66%)
F   19.98 (+4.12%)
DIS   144.60 (-0.21%)
PFE   54.41 (+1.27%)
ACB   6.22 (-3.12%)
AMC   31.31 (-7.75%)
BA   193.13 (-2.39%)
S&P 500   4,585.36 (+0.40%)
DOW   34,529.70 (+0.13%)
QQQ   395.37 (+0.39%)
AAPL   168.35 (+1.85%)
MSFT   335.93 (+1.62%)
FB   317.19 (-2.24%)
GOOGL   2,879.63 (+1.47%)
AMZN   3,496.29 (-0.31%)
TSLA   1,137.60 (-0.63%)
NVDA   323.38 (-1.03%)
BABA   125.05 (-1.94%)
NIO   39.58 (+1.15%)
CGC   10.31 (-3.73%)
AMD   153.32 (-3.19%)
GE   95.00 (+0.01%)
MU   87.25 (+3.87%)
T   22.45 (-1.66%)
F   19.98 (+4.12%)
DIS   144.60 (-0.21%)
PFE   54.41 (+1.27%)
ACB   6.22 (-3.12%)
AMC   31.31 (-7.75%)
BA   193.13 (-2.39%)
S&P 500   4,585.36 (+0.40%)
DOW   34,529.70 (+0.13%)
QQQ   395.37 (+0.39%)
AAPL   168.35 (+1.85%)
MSFT   335.93 (+1.62%)
FB   317.19 (-2.24%)
GOOGL   2,879.63 (+1.47%)
AMZN   3,496.29 (-0.31%)
TSLA   1,137.60 (-0.63%)
NVDA   323.38 (-1.03%)
BABA   125.05 (-1.94%)
NIO   39.58 (+1.15%)
CGC   10.31 (-3.73%)
AMD   153.32 (-3.19%)
GE   95.00 (+0.01%)
MU   87.25 (+3.87%)
T   22.45 (-1.66%)
F   19.98 (+4.12%)
DIS   144.60 (-0.21%)
PFE   54.41 (+1.27%)
ACB   6.22 (-3.12%)
AMC   31.31 (-7.75%)
BA   193.13 (-2.39%)
NASDAQ:COGT

Cogent Biosciences Stock Forecast, Price & News

$7.74
-0.18 (-2.27%)
(As of 12/1/2021 01:57 PM ET)
Add
Compare
Today's Range
$7.73
$8.15
50-Day Range
$7.60
$10.81
52-Week Range
$5.83
$13.90
Volume
3,302 shs
Average Volume
320,576 shs
Market Capitalization
$308.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.88
30 days | 90 days | 365 days | Advanced Chart
Receive COGT News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Cogent Biosciences logo

About Cogent Biosciences

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Headlines

SVB Leerink Begins Coverage on Cogent Biosciences (NASDAQ:COGT)
November 14, 2021 |  americanbankingnews.com
Hedge Funds Are Dumping Cogent Biosciences, Inc. (COGT)
October 29, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COGT
Fax
N/A
Employees
15
Year Founded
N/A

Sales & Book Value

Annual Sales
$7.87 million
Book Value
$3.83 per share

Profitability

Net Income
$-74.81 million
Pretax Margin
-28,717.31%

Debt

Price-To-Earnings

Miscellaneous

Free Float
39,508,000
Market Cap
$308.45 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/15/2022

MarketRank

Overall MarketRank

1.97 out of 5 stars

Medical Sector

660th out of 1,392 stocks

Pharmaceutical Preparations Industry

310th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Cogent Biosciences (NASDAQ:COGT) Frequently Asked Questions

Is Cogent Biosciences a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cogent Biosciences stock.
View analyst ratings for Cogent Biosciences
or view top-rated stocks.

Are investors shorting Cogent Biosciences?

Cogent Biosciences saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,410,000 shares, a drop of 20.8% from the October 31st total of 1,780,000 shares. Based on an average trading volume of 283,700 shares, the short-interest ratio is currently 5.0 days. Approximately 4.1% of the shares of the stock are short sold.
View Cogent Biosciences' Short Interest
.

When is Cogent Biosciences' next earnings date?

Cogent Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Cogent Biosciences
.

How were Cogent Biosciences' earnings last quarter?

Cogent Biosciences, Inc. (NASDAQ:COGT) posted its earnings results on Wednesday, November, 10th. The technology company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.07.
View Cogent Biosciences' earnings history
.

What price target have analysts set for COGT?

4 equities research analysts have issued 1-year price targets for Cogent Biosciences' stock. Their forecasts range from $20.00 to $31.00. On average, they anticipate Cogent Biosciences' share price to reach $24.33 in the next year. This suggests a possible upside of 214.4% from the stock's current price.
View analysts' price targets for Cogent Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Cogent Biosciences' key executives?

Cogent Biosciences' management team includes the following people:
  • Andrew R. Robbins, President, Chief Executive Officer & Director
  • John L. Green, Chief Financial & Accounting Officer (LinkedIn Profile)
  • Jessica Sachs, Chief Medical Officer
  • John Robinson, Chief Scientific Officer
  • Brad Barnett, Chief Technology Officer

What other stocks do shareholders of Cogent Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ), Nutanix (NTNX), OPKO Health (OPK), STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM).

What is Cogent Biosciences' stock symbol?

Cogent Biosciences trades on the NASDAQ under the ticker symbol "COGT."

Who are Cogent Biosciences' major shareholders?

Cogent Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.86%), Janus Henderson Group PLC (6.26%), Candriam Luxembourg S.C.A. (4.84%), Commodore Capital LP (4.80%), Polar Capital Holdings Plc (3.08%) and Point72 Asset Management L.P. (2.52%).
View institutional ownership trends for Cogent Biosciences
.

Which institutional investors are selling Cogent Biosciences stock?

COGT stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Point72 Asset Management L.P., California State Teachers Retirement System, New York State Common Retirement Fund, Moore Capital Management LP, The Manufacturers Life Insurance Company , Schonfeld Strategic Advisors LLC, and Virtus ETF Advisers LLC.
View insider buying and selling activity for Cogent Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Cogent Biosciences stock?

COGT stock was purchased by a variety of institutional investors in the last quarter, including Commodore Capital LP, Polar Capital Holdings Plc, Platinum Investment Management Ltd., Goldman Sachs Group Inc., Janus Henderson Group PLC, BlackRock Inc., Franklin Resources Inc., and AXA S.A..
View insider buying and selling activity for Cogent Biosciences
or or view top insider-buying stocks.

How do I buy shares of Cogent Biosciences?

Shares of COGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cogent Biosciences' stock price today?

One share of COGT stock can currently be purchased for approximately $7.74.

How much money does Cogent Biosciences make?

Cogent Biosciences has a market capitalization of $308.45 million and generates $7.87 million in revenue each year. The technology company earns $-74.81 million in net income (profit) each year or ($7.31) on an earnings per share basis.

How many employees does Cogent Biosciences have?

Cogent Biosciences employs 15 workers across the globe.

What is Cogent Biosciences' official website?

The official website for Cogent Biosciences is www.cogint.com.

Where are Cogent Biosciences' headquarters?

Cogent Biosciences is headquartered at 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431.

How can I contact Cogent Biosciences?

Cogent Biosciences' mailing address is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. The technology company can be reached via phone at (617) 945-5576 or via email at [email protected].


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.